Skip to main content
Fig. 1 | BMC Cardiovascular Disorders

Fig. 1

From: Ticagrelor and clopidogrel suppress NF-κB signaling pathway to alleviate LPS-induced dysfunction in vein endothelial cells

Fig. 1

Ticagrelor and clopidogrel inhibit the LPS-induced expression of TNFα, IL-1, IL-6, IL-8, and IL-2. a: HUVECs were treated with different concentrations of ticagrelor and clopidogrel, separately, for 12 h, 24 h or 48 h. Cell viability was detected by CCK-8 assays at the indicated time points. b-c: HUVECs were treated with DMSO, ticagrelor, clopidogrel, DMSO plus LPS and CD14, ticagrelor plus LPS and CD14, and clopidogrel plus LPS and CD14, separately, for 16 h. The mRNA levels of TNFα (b), IL-1 (c), IL-6 (d), IL-8 (e), and IL-2 (f) were detected by qPCR (n = 3; *, p < 0.05; **, p < 0.01; and ***, p < 0.001)

Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us